PRO

Investing in psychedelic companies has become increasingly popular in the past few years. Here at Psychedelic Invest, our goal is to connect you to the resources that you need to make educated decisions when it comes to your money.

This exhaustive report created by Innowell and Psychedelic Invest highlights the growing ketamine clinic industry.

No matter what happens with stock prices or the economy, one thing is certain… Companies (and individuals) will never stop conducting the necessary research on psychedelic compounds.

This past year was no exception. One could even argue that 2022 proved to be the most progressive when it comes to progressing clinical trials and unveiling success stories that need to be heard.

From the outside looking in, psychedelics had a monumental year. Mainstream media has been talking about it – telling stories and building momentum. The stigma is slowly breaking down due to this momentum.

But if you look beyond the surface, you’ll see that 2022 did not serve those that are participating in this industry. Valuations shot down as stock prices corrected. Overall, there is a sense that capital is drying up.

That said, there are still plenty of storylines to follow. There is growth as a whole, you just have to know where to look.